Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Amgen Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)’. The study aims to evaluate the efficacy of combining tarlatamab with durvalumab compared to durvalumab alone in extending overall survival in patients with extensive-stage small-cell lung cancer (ES-SCLC).
The study tests two interventions: an experimental combination of tarlatamab and durvalumab, and durvalumab alone as an active comparator. Both drugs are administered via intravenous infusion, with tarlatamab given every two weeks and durvalumab every four weeks.
This interventional study employs a randomized, parallel assignment model without masking, focusing on treatment as its primary purpose. The open-label design allows all participants and researchers to know which treatment is being administered.
The study began on June 5, 2024, with an estimated completion date yet to be specified. The latest update was submitted on August 20, 2025, indicating ongoing recruitment and progress.
This study could significantly impact Amgen’s stock performance and investor sentiment, particularly if the combination therapy proves more effective than the current standard. As competition in the oncology sector intensifies, successful outcomes could enhance Amgen’s market position.
The study is currently ongoing, with further details accessible on the ClinicalTrials portal.